Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

EBIT
Harbor Small Cap Earners ETF
stock NYSE ETF

At Close
Sep 30, 2026
0.00USD-100.000%(-37.52)65
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-37.52)0
After-hours
Oct 1, 2026 4:10:30 PM EDT
37.82USD0.000%(+37.82)4
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrends
EBIT Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
EBIT Specific Mentions
As of Oct 2, 2026 5:30:10 AM EDT (1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
13 hr ago • u/bradbodnick • r/mauerstrassenwetten • tägliche_diskussion_october_01_2026 • C
Autsch
$NKE | NIKE Q1 27 EARNINGS:
• REVENUE: $11.21B (EST $11.33B)
• EPS: 48C VS 49C Y/Y
• GROSS MARGIN: 42.8% VS 42.2% Y/Y
• NIKE BRAND REVENUE: $10.95B (EST $11.09B)
• GREATER CHINA EBIT: $248M (EST $312.2M)
• INVENTORY: $7.8B (EST $7.96B)
sentiment -0.15
13 hr ago • u/_hiddenscout • r/stocks • rstocks_daily_discussion_options_trading_thursday • C
$NKE
EPS $0.48, est. $0.44, vs. $0.49 y/y
Revenue $11.21B, est. $11.33B
Nike Brand revenue $10.95B, est. $11.09B
Gross margin 42.8%, vs. 42.2% y/y
Greater China EBIT $248M, est. $312.2M
Inventory $7.80B, est. $7.96B
Expects FY27 revenue to decline high-single digits
Expects adjusted EPS $1.15 to $1.35 for fiscal 2027
sentiment -0.15
13 hr ago • u/CMTTrader • r/wallstreetbets • what_are_your_moves_tomorrow_october_2_2026 • C
\*NIKE 1Q REV. $11.21B, EST. $11.33B (-1.1%)
\*NIKE 1Q EPS 48C VS. 49C Y/Y
\*NIKE 1Q NET INCOME $712M, EST. $638.2M (+12%)
\*NIKE 1Q GROSS MARGIN 42.8% VS. 42.2% Y/Y
\*NIKE 1Q GREATER CHINA EBIT $248M, EST. $312.2M (-21%)
sentiment -0.15
20 hr ago • u/BigBelly_Dad • r/mauerstrassenwetten • könnt_ihr_euch_ein_deutsches_auto_leisten • C
Lang lebe das Dienstwagenprivileg. Wie du schon schreibst: Die Fahrzeugpreise sind nur noch auf Firmenflotten ausgelegt, nicht auf Privatkäufer. Zwei Drittel der Neuwagen werden gewerblich zugelassen, da braucht man sich nicht wundern.
Und das aktuelle Geheule der Autokonzerne? Meistens keine Verluste, „nur“ das EBIT ist runtergegangen. Übersetzt: Die tun so, als stünden sie tief in den roten Zahlen, dabei ist „bloß“ der Gewinn kleiner. Mercedes hat gerade eine weitere Milliarde für Aktienrückkäufe angekündigt. So sieht also Krise aus. Das Geld ist da, es landet halt bei den Aktionären und in den Vorstandsboni statt beim Kunden. Anders, als der Eindruck, der gerade in den Medien breitgetreten wird - ich sehe dich, Springer-Presse. Danke für nichts.
Und wer mir jetzt mit den hohen Produktionskosten in DE kommt: Schon mal über die riesigen Rabatte nachgedacht, die beim Autoneukauf über Schwerbehindertenausweis, Verbandsmitgliedschaften usw. trotzdem noch drin sind? Die kannst du nur geben, wenn du sie vorher draufgeschlagen hast. Der Listenpreis ist für Leute, die nicht verhandeln.
sentiment -0.98
13 hr ago • u/bradbodnick • r/mauerstrassenwetten • tägliche_diskussion_october_01_2026 • C
Autsch
$NKE | NIKE Q1 27 EARNINGS:
• REVENUE: $11.21B (EST $11.33B)
• EPS: 48C VS 49C Y/Y
• GROSS MARGIN: 42.8% VS 42.2% Y/Y
• NIKE BRAND REVENUE: $10.95B (EST $11.09B)
• GREATER CHINA EBIT: $248M (EST $312.2M)
• INVENTORY: $7.8B (EST $7.96B)
sentiment -0.15
13 hr ago • u/_hiddenscout • r/stocks • rstocks_daily_discussion_options_trading_thursday • C
$NKE
EPS $0.48, est. $0.44, vs. $0.49 y/y
Revenue $11.21B, est. $11.33B
Nike Brand revenue $10.95B, est. $11.09B
Gross margin 42.8%, vs. 42.2% y/y
Greater China EBIT $248M, est. $312.2M
Inventory $7.80B, est. $7.96B
Expects FY27 revenue to decline high-single digits
Expects adjusted EPS $1.15 to $1.35 for fiscal 2027
sentiment -0.15
13 hr ago • u/CMTTrader • r/wallstreetbets • what_are_your_moves_tomorrow_october_2_2026 • C
\*NIKE 1Q REV. $11.21B, EST. $11.33B (-1.1%)
\*NIKE 1Q EPS 48C VS. 49C Y/Y
\*NIKE 1Q NET INCOME $712M, EST. $638.2M (+12%)
\*NIKE 1Q GROSS MARGIN 42.8% VS. 42.2% Y/Y
\*NIKE 1Q GREATER CHINA EBIT $248M, EST. $312.2M (-21%)
sentiment -0.15
20 hr ago • u/BigBelly_Dad • r/mauerstrassenwetten • könnt_ihr_euch_ein_deutsches_auto_leisten • C
Lang lebe das Dienstwagenprivileg. Wie du schon schreibst: Die Fahrzeugpreise sind nur noch auf Firmenflotten ausgelegt, nicht auf Privatkäufer. Zwei Drittel der Neuwagen werden gewerblich zugelassen, da braucht man sich nicht wundern.
Und das aktuelle Geheule der Autokonzerne? Meistens keine Verluste, „nur“ das EBIT ist runtergegangen. Übersetzt: Die tun so, als stünden sie tief in den roten Zahlen, dabei ist „bloß“ der Gewinn kleiner. Mercedes hat gerade eine weitere Milliarde für Aktienrückkäufe angekündigt. So sieht also Krise aus. Das Geld ist da, es landet halt bei den Aktionären und in den Vorstandsboni statt beim Kunden. Anders, als der Eindruck, der gerade in den Medien breitgetreten wird - ich sehe dich, Springer-Presse. Danke für nichts.
Und wer mir jetzt mit den hohen Produktionskosten in DE kommt: Schon mal über die riesigen Rabatte nachgedacht, die beim Autoneukauf über Schwerbehindertenausweis, Verbandsmitgliedschaften usw. trotzdem noch drin sind? Die kannst du nur geben, wenn du sie vorher draufgeschlagen hast. Der Listenpreis ist für Leute, die nicht verhandeln.
sentiment -0.98
1 day ago • u/PrimarySourceArb • r/ValueInvesting • netease_earns_metas_margins_at_metas_growth_rate • C
The 'spiritual opium' editorial was real and the license freeze lasted nine months. NetEase's EBIT margins during that period: 18.7% in FY2021, 20.3% in FY2022, 26.8% in FY2023, 28.1% in FY2024, 31.8% in FY2025. The margins didn't hold. They expanded from 19% to 32% through the worst regulatory cycle in Chinese gaming history. The risk isn't gone, but NetEase's track record through it is the best data point on how much damage a crackdown actually does to this specific business.
sentiment -0.22
2 days ago • u/JamessF45 • r/ValueInvesting • nextil_nxt_h1_2026_financial_results_summary • Stock Analysis • B
Here is a summary of Nextil's H1 2026 financial results compared to H1 2025 based on their latest earnings report.
**Key Financial Metrics (H1 2025 vs H1 2026)**
**Revenue**: 27.2 million EUR on a like-for-like basis, up 66.4% year over year from 16.3 million EUR. Normalized revenue including the Sindutex acquisition reached 32.5 million EUR (+99%). 
**EBITDA**: 5.9 million EUR like-for-like, up 78.2% from 3.3 million EUR. This increases the EBITDA margin to 21.8%. Normalized EBITDA was 7.2 million EUR. 
**EBIT (Operating Profit)**: 4.2 million EUR, up 164.6% from 1.6 million EUR. Margin expanded significantly due to operating leverage. 
**Net Profit:** 3.2 million EUR, up 165.2% from 1.2 million EUR. Normalized net profit reached 4.4 million EUR. 
Operating Cash Flow: 4.3 million EUR, up 72.0% from 2.5 million EUR. 
**Net Financial Debt**: 23.9 million EUR. Net Debt to LTM EBITDA sits at 1.98x, which remains well below their strategic ceiling of 2.5x. 
**Earnings Per Share (EPS)**: Increased by 118.8% to 0.0070 EUR per share, absorbing the dilution from recent debt-to-equity conversions. 
**Operational Overview**
**1. Operating Leverage**: Higher production volume on existing infrastructure allows fixed cost absorption, expanding EBIT margins to 15.5%. 
**2. E Growth**: The European Hub grew revenue by 50.8%, while the Americas Hub doubled its sales (+114.6%) backed by CAFTA partnerships and Greendyes technology. 
**3. Balance Sheet**: Debt-to-equity conversions helped increase Total Equity to 17.8 million EUR while keeping leverage under control.
sentiment 0.95
2 days ago • u/SvennisTheDennis • r/ISKbets • aktietips_freemelt • C
Emission är alltid en risk i småbolag men jag är inte så orolig för det gällande var freemelt befinner sig just nu. Att räkna att pengarna är slut q1 27 förutsätter totalt stopp i orderflödet. Som nämnt tidigare tror jag ca 10-30% betalas upfront i den senaste mega ordern och services manufacturing delen ser bara ut att växa framöver. Med en stark orderpipeline på ca 100 MSEK tillförs kassa kontinuerligt, vilket flyttar fram emissionsrisken. Samtidigt fasas gamla aktiverade R&D-kostnader ut ur balansräkningen och snyggar till EBIT, medan en växande bas av support- och serviceavtal ger återkommande intäkter med hög marginal som dämpar den faktiska kassaförbränningen. Risken för emission finns om orderflödet viker, men med dagens orderbok köper sig bolaget betydligt mer tid än vad en statisk burn rate-kalkyl visar.
sentiment -0.49
2 days ago • u/RafaelWanderpfad • r/Finanzen • bundesregierung_beschließt_pflegereform_das_sind • C
Lol, diese Steuern zahlt im echten Leben exakt EIN Unternehmer: derjenige, der den schlechtesten Steuerberater Deutschlands hat. Kein Mensch mit Verstand schüttet sich als Firmeninhaber Millionen privat aufs Girokonto aus. Stichwort: Holding-Struktur (§ 8b KStG). Die operative GmbH macht Gewinn (30% Steuer). Die Knete wandert in die Mutter-Holding – Steuer darauf: **1,5%** (kein Tippfehler). Da drin wird das Geld spottbillig parkiert, reinvestiert, in Aktien gesteckt oder in Immo-GmbHs verschoben. Privat zahlt man sich nur das aus, was man zum Leben braucht. Und die Hälfte des Privatelebens (Firmenwagen, MacBooks, Restaurantbesuche, "Geschäftsreisen") läuft vorher eh schon als Betriebsausgabe übers EBIT.
sentiment -0.93
2 days ago • u/PrimarySourceArb • r/ChinaStocks • netease_earns_metas_margins_at_metas_growth_rate • 💡 Due Diligence • B
I put together a comp table of 14 internet companies: eight listed in Hong Kong and six in the US. Matched them on consensus EPS growth rates and GAAP EBIT margins to try to separate the jurisdiction discount from the fundamental discount.
The cleanest pair: NetEase grows EPS at 18.9% per year with 40% EBIT margins. Meta grows at 18.0% with 41%. Growth and margins nearly identical. NetEase trades at 11.7x forward earnings. Meta at 21.6x. That is a 46% discount. NetEase earns from gaming, not advertising, so the businesses are not identical. But at matched growth and margins, the multiple gap is hard to explain without jurisdiction.
At every matched growth rate where margins also match, the HK name trades cheaper. The discount ranges from 44% to 46%.
The "Chinese companies hoard cash" thing. I went through the actual payout data. It has not been accurate since at least 2023.
* Tencent total shareholder yield (dividends + net buybacks after SBC dilution): 2.4%. Meta: 1.4%.
* [JD.com](http://jd.com/) dividend yield alone: 3.8%, 70% payout ratio.
* NetEase total yield: 2.9%, per-share dividend CAGR of roughly 18% over the past four and a half years.
So the discount is not about growth and not about payouts. I went through what it does price: VIE ownership structure (low to medium risk), cash repatriation friction (low risk, every company in the sample has been paying and growing dividends for years), and geopolitical tail risk (medium to high, the one that actually matters).
Wrote the whole thing up with all 14 companies, the methodology, and a risk framework: [https://darrenleung1.substack.com/p/chinese-tech-is-cheap-how-much-of](https://darrenleung1.substack.com/p/chinese-tech-is-cheap-how-much-of)
sentiment -0.83
2 days ago • u/Heavy-Sherbet-4765 • r/Finanzen • bundesregierung_beschließt_pflegereform_das_sind • C
Nö. Deutschland ist bei 2 Gruppen im internationalen Vergleich absolutes Hochsteuerland:
1. Singles mit regulären Arbeitseinkommen
2. Unternehmensbesitzer: Im OECD Vergleich besteuern nur 3 Länder von EBIT bis Geld beim Firmenbesitzer auf dem Konto höher.
Trotzdem fahren Linke seit Jahren eine sehr erfolgreiche Kampagne, dass Gruppe 2 angeblich in Deutschland gar nicht besteuert wird.
Wer übrigens tatsächlich in Deutschland eine sehr geringe Steuer- und Abgabenlast im internationalen Vergleich hat: Familien mit Kindern und Einkommen aus Arbeit.
sentiment 0.00
2 days ago • u/Economy_Explorer4256 • r/IndianStreetBets • indian_pharma_stocks_jumped_on_a_0_tariff • Discussion • B
Nifty Pharma was up over 1% intraday recently while the broader Nifty 50 fell, on news that the US created a 0% tariff route for certain pharma products from India. Dr. Reddy's, Gland Pharma, Mankind and a few others jumped 2-3%. Reading into the actual policy though, the exemption is a lot narrower than the market reaction suggests.
Background: the US had put a 100% tariff on specified patented pharmaceuticals and biologics under Section 232. What changed is that the US Commerce Department carved out a zero-tariff path, but only for specific categories: rare-disease drugs, fertility treatments, cell and gene therapies, antibody-drug conjugates, animal pharma, nuclear medicines, plasma-derived therapies. India is one of several eligible countries (EU, Japan, South Korea, UK, Taiwan also qualify), so this isn't an India-specific advantage.
The bigger deal buried in the same announcement: generic pharmaceuticals and their ingredients are currently not subject to these tariffs at all. That matters more for India specifically, since generics are roughly 30% of India's $31 billion pharma exports and the US is the single largest buyer.
So a company's actual exposure depends on its product mix, not just "does it sell to the US." A rough breakdown of how it splits:
Biocon's biosimilars business (\~₹10,431 crore FY26 revenue) is outside the Section 232 tariffs entirely, so it isn't really a beneficiary of this specific exemption even though people are lumping it in.
Aurobindo has a large US generics business, but large US revenue doesn't automatically mean large tariff exposure, since most of what they sell falls under the generics carve-out anyway.
Cipla and Zydus have some product lines (fertility drugs, animal health) that fall inside the qualifying categories, so there's more direct relevance there.
Divi's is really an API/manufacturing supply-chain story, not a tariff-exemption story at all.
The framework that seemed most useful: don't ask "did the tariff go away," ask "how much of this specific company's EBIT was ever exposed to it in the first place." A stock can rally on a headline and still not have much of its actual earnings protected by what changed.
Anyone here holding pharma right now, are you checking each company's actual US/specialty revenue split before reacting to news like this, or riding the sector-wide sentiment?
sentiment 0.83
2 days ago • u/Twisteesmt • r/ValueInvesting • which_stocks_are_you_holding_for_the_next_20 • C
I been doing more research let me know what you think
# Growth Stocks Research — Concise Report
**As of 30 September 2026**
# 1. Objective
The purpose of this research was to identify **genuine growth stocks with potential for further fundamental rerating**, rather than simply companies with high historical growth.
Your investment framework prioritises:
* Revenue acceleration
* Operating leverage and margin expansion
* Improving unit economics
* Rising EPS
* Strong/free-cash-flow potential
* Large credible markets
* Underappreciated business change
* Valuation versus implied future growth
* Catalysts over the next 12–24 months
* Risk-adjusted returns and opportunity cost
The framework explicitly allows **“wait”, “watchlist” or “no trade”** when valuation or evidence is insufficient.
# 2. Initial growth-stock universe
The research identified the following broad groups:
# AI / semiconductor infrastructure
**NVDA, CRDO, ANET, MU, SNDK, FN, AEIS, SIMO**
# AI power / data-centre infrastructure
**VRT, PWR, FIX, STRL, MOD, FPS**
# Software / AI monetisation
**APP, PLTR, RDDT, GLBE, CRWD, AVPT**
The key conclusion was that **AI infrastructure should not be viewed purely as GPU exposure**.
The broader investment chain is:
**AI models → GPUs → networking → memory → power → cooling → data-centre construction → grid infrastructure**
This creates opportunities well beyond NVIDIA.
# 3. Most interesting companies from the Excel screener
The uploaded screener contained approximately **340 stocks**.
The strongest fundamental candidates identified were:
|Stock|Revenue growth|5Y Revenue CAGR|5Y EBIT CAGR|5Y FCF CAGR|
|:-|:-|:-|:-|:-|
|**FPS**|**78.0%**|**34.9%**|**61.5%**|**164.6%**|
|**CRDO**|**86.1%**|**35.5%**|**49.1%**|**83.3%**|
|**SIMO**|**111.0%**|12.4%|34.1%|**150.2%**|
|**STRL**|**64.2%**|**25.3%**|31.9%|30.3%|
|**RDDT**|**53.4%**|**29.3%**|43.1%|66.2%|
|**GLBE**|**38.9%**|**22.6%**|**54.6%**|31.3%|
|**FN**|**31.1%**|**22.3%**|39.0%|**119.3%**|
|**AEIS**|**34.9%**|18.3%|**45.0%**|78.0%|
|**MOD**|**27.6%**|**22.8%**|42.0%|78.4%|
|**AVPT**|21.7%|**23.4%**|**55.1%**|43.0%|
These numbers are **screening projections**, not guarantees.
# 4. Key company conclusions
# FPS — Forgent Power Solutions
Potentially the most interesting discovery.
Excel projections:
* Revenue: **+78%**
* 5Y revenue CAGR: **34.9%**
* EBIT CAGR: **61.5%**
* FCF CAGR: **164.6%**
Actual FY2026:
* Revenue **+89%**
* Net income **+508%**
* Adjusted EBITDA **+163%**
* Bookings **+375%**
* Backlog **+256%**
* FY2027 revenue guidance: **$2.4–2.6bn**
* EBITDA guidance: **$575–625m**
**Thesis:** AI/data-centre power infrastructure with significant operating leverage.
# CRDO — Credo Technology
Excel:
* Revenue growth: **86.1%**
* 5Y revenue CAGR: **35.5%**
* EBIT CAGR: **49.1%**
* FCF CAGR: **83.3%**
Latest quarter:
* Revenue: **$479m**
* YoY growth: **114.7%**
* Net income growth: **140%**
* Non-GAAP gross margin: approximately **68%**
* Next-quarter revenue guidance: **$525–535m**
**Thesis:** One of the cleanest high-growth AI networking/connectivity businesses.
**Main risk:** valuation and the assumption that extremely high growth persists.
# STRL — Sterling Infrastructure
Excel:
* Revenue growth: **64.2%**
* 5Y revenue CAGR: **25.3%**
* EBIT CAGR: **31.9%**
* FCF CAGR: **30.3%**
Actual Q2:
* Revenue **+90%**
* Organic growth \~**50%**
* Net income **+120%**
* EBITDA **+104%**
* Backlog **+116%**
* 2026 revenue guidance: approximately **$4.0–4.15bn**
**Thesis:** Data-centre infrastructure beneficiary without being a semiconductor company.
# GLBE — Global-e
Excel:
* Revenue growth: **38.9%**
* 5Y revenue CAGR: **22.6%**
* EBIT CAGR: **54.6%**
* Net-income CAGR: **54.2%**
Actual Q2:
* GMV **+44%**
* Revenue **+39%**
* Adjusted EBITDA margin **20.9%**
* Margin expansion: **+300 bps**
**Thesis:** Strong revenue growth combined with operating leverage.
# RDDT — Reddit
Excel:
* Revenue growth: **53.4%**
* 5Y revenue CAGR: **29.3%**
* EBIT CAGR: **43.1%**
* FCF CAGR: **66.2%**
Actual Q2:
* Revenue **+61%**
* DAUq **+18%**
* WAUq **+24%**
* Net income **+183%**
* EBITDA **+106%**
* FCF **+135%**
**Thesis:** User growth is translating into substantially faster monetisation and cash-flow growth.
# FN — Fabrinet
Excel:
* Revenue growth: **31.1%**
* 5Y revenue CAGR: **22.3%**
* EBIT CAGR: **39.0%**
* FCF CAGR: **119.3%**
Actual FY2026:
* Revenue **+36%**
* Revenue: **$4.64bn**
* Q4 revenue **+45%**
* EPS: **$13.05 vs $9.17**
**Thesis:** Less obvious optical/AI infrastructure exposure with strong cash-flow economics.
# AEIS — Advanced Energy Industries
Excel:
* Revenue growth: **34.9%**
* 5Y revenue CAGR: **18.3%**
* EBIT CAGR: **45.0%**
* FCF CAGR: **78.0%**
Q2 2026:
* Revenue **+30%**
* Semiconductor revenue **+33%**
* Data-centre revenue **+35%**
* Gross margin: **41.9%**
* Operating cash flow: **$86m**
Management expected data-centre revenue to grow **>50% in 2026**.
**Thesis:** Power conversion + semiconductor/data-centre exposure.
# MOD — Modine
Excel:
* Revenue growth: **27.6%**
* 5Y revenue CAGR: **22.8%**
* EBIT CAGR: **42.0%**
* FCF CAGR: **78.4%**
Q1 FY2027:
* Revenue **+28%**
* EPS **+44%**
* Data-centre revenue **+90%**
* FY2027 sales outlook **+20–35%**
**Thesis:** Thermal-management/cooling exposure to data centres.
# 5. Important cyclical candidates
# MU — Micron
Not a conventional long-duration compounder, but a major **earnings inflection**.
Q3 FY2026:
* Revenue: **$41.46bn**
* Prior-year quarter: **$9.30bn**
* Operating cash flow: **$25.39bn**
* Net income: **$28.24bn**
The thesis is:
**HBM + AI memory demand → dramatically higher earnings → potential valuation rerating.**
The risk is that memory remains cyclical.
# SIMO — Silicon Motion
Excel:
* Revenue growth: **111%**
* EPS growth: **206%**
* EBIT growth: **411%**
* FCF CAGR: **150%**
Very attractive numbers, but much of this represents **earnings/base-effect acceleration**.
Therefore:
**High-growth/inflection trade rather than automatically a 10-year compounder.**
# SNDK
Extremely strong AI-storage/memory earnings story, but the share price had already increased roughly **1,400%+ over the preceding year**.
Therefore the central question becomes:
>How much of the future earnings improvement is already priced in?
# 6. Mega-cap growth
# NVDA
Still unquestionably a growth company:
* Q2 FY2027 revenue: **$96.2bn**
* Revenue growth: **+106%**
* Data-centre revenue: **$89bn**
* Data-centre growth: **+117%**
* Gross margin: **75%**
However, NVIDIA is now a **mega-cap growth company**, not an early-stage growth discovery.
The investment challenge is the amount of future growth already embedded in its valuation.
# PLTR
Fundamentally exceptional:
* Q2 revenue: **$1.935bn**
* Revenue growth: **+93%**
* U.S. commercial revenue: **+149%**
* Adjusted operating margin: **62%**
* 2026 revenue-growth guidance: approximately **82%**
But valuation was extremely demanding, around **99× forward earnings** in the data reviewed.
Therefore:
**Excellent growth business ≠ automatically attractive investment at any price.**
# APP
One of the more interesting growth/valuation combinations:
* Q2 revenue: **$1.924bn**
* Revenue growth: **+53%**
* EBITDA growth: **+58%**
* FCF: **$863m**
APP's AI-driven advertising platform is generating substantial operating leverage.
# 7. Names requiring caution
The screener produces some spectacular-looking numbers that need interpretation.
# KLIC
* EPS growth: **98,148%**
* EBIT growth: **2,781%**
* 5Y EBIT CAGR: **113%**
These numbers are dominated by a low/base-effect situation and should **not** be interpreted as sustainable 98,000% growth.
# HUBS
* EPS growth: **1,452%**
* EBIT growth: **6,054%**
But actual revenue growth is closer to the high-teens.
# APPN
* EPS growth: **6,482%**
* EBIT growth: **720%**
Again, largely an earnings-recovery/operating-leverage effect rather than equivalent revenue growth.
# 8. Final research shortlist
After combining the **Excel projections + actual operating evidence + business quality**, the most interesting group became:
# Highest-priority research
**FPS** — power distribution / data centres
**CRDO** — AI connectivity
**STRL** — data-centre infrastructure
**GLBE** — e-commerce infrastructure
**RDDT** — advertising/platform monetisation
**FN** — optical/AI manufacturing
**AEIS** — power conversion
**MOD** — thermal/data-centre infrastructure
# Secondary
**SIMO** — storage/controller inflection
**MU** — HBM/memory cycle
**AVPT** — software compounder
**NVT** — electrical/data-centre infrastructure
**SANM** — electronics manufacturing
**GRAB** — platform growth
**FLYW** — fintech/software
**GWRE** — insurance software
**TOST** — restaurant software/payments
# High-quality but valuation-sensitive
**NVDA**
**ANET**
**PLTR**
**APP**
**CRWD**
# 9. Overall conclusion
The research changed the focus from simply asking:
>**“Which stocks are growing fastest?”**
to:
>**“Which companies have accelerating fundamentals that the market may not yet have fully priced?”**
The most interesting **fundamental inflection candidates from the spreadsheet** are:
**FPS → CRDO → STRL → GLBE → RDDT → FN → AEIS → MOD**
The most interesting **cyclical earnings-inflation candidates** are:
**MU → SIMO → SNDK**
The **mega-cap/established growth leaders** are:
**NVDA → ANET → PLTR → APP → CRWD**
The biggest unresolved question is **valuation**. Your spreadsheet establishes the growth side very well, but the next stage needs to determine whether these companies are **cheap, fairly valued or already priced for near-perfect execution**. Your framework explicitly identifies this as a required question before making an investment decision.
**Bottom line:** the research has reduced the original \~340-stock universe to roughly **8–15 names worth serious second-stage due diligence**, with **FPS and CRDO standing out most strongly from the combination of projected growth and current fundamental evidence.**
sentiment 1.00
2 days ago • u/dvdmovie1 • r/stocks • rstocks_daily_discussion_wednesday_sep_30_2026 • C
> buy HSY? WMT? RDDT? ASTS? GOOG? NFLX? AMZN?
Out of that list, an unenthusiastic yes to AMZN although Bezos will probably sell more soon. Maybe the GOOG convertible pfd (GOOGM). ASTS slight in the mid 50's. WMT was way expensive vs history still not reasonable. Not really interested in cpg names like HSY although probably should be given that so many of them have been obliterated. The problem I have is that most of them are poorly run, among other problems. CPB actually has an okay stable of brands, but the company isn't well run and FY27 not looking great (Net sales decline of 2% to 4%1
, adjusted EBIT decline of 7% to 12%,) Any tunaround and the stock could take off (25% short interest), but something good has to happen and they've struggled to accomplish that.
sentiment -0.36


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC